Minerva Neurosciences | NERV - Operating Profit


Minerva Neurosciences reported $-21.85M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Adma Biologics USD 50.29M 12.46M Mar/2026
ALKERMES USD -48.28M 37.33M Mar/2026
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
AstraZeneca USD 7.11B 4.14B Mar/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Cipla INR 8.88B 2.74B Jun/2026
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -9.02M 65.06M Mar/2026
CSL USD 2.64B 1.97B Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
J&J USD 7.48B 860M Jun/2026
Merck USD -1.88B 8.12B Mar/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Neurocrine Biosciences USD 214.6M 13.3M Mar/2026
Novartis USD 4.24B 171M Mar/2026
Novavax USD 20.94M 100.32M Dec/2025
Pfizer USD 4.99B 340M Mar/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 1.94B 239M Mar/2026
Takeda JPY -13.62B 182.44B Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024